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ABSTRACT 
COMBINATION TREATMENT WITH CONJUGATED LINOLEIC ACID AND 
NITRITE PROTECTS AGAINST MYOCARIDAL INFARCTION 
 
Natia Qipshidze Kelm 
August 5, 2015 
  
         According to the CDC, the most common type of heart disease is coronary 
artery disease, which frequently leads to myocardial infarction (MI). Therapeutic 
approaches to lessen the resulting cardiovascular injury associated with MI are 
limited. Recently, the management paradigm for cardiac injury has entered the 
molecular era and microRNAs (miRNAs) have been shown to act as negative 
regulators of gene expression by inhibiting mRNA translation and/or stimulating 
mRNA degradation. A single miRNA can modulate physiological or disease 
phenotypes by regulating whole functional systems. Importantly, miRNAs can 
regulate cardiac function, thereby modulating heart muscle contraction, heart 
growth and morphogenesis. MicroRNA-499 (miRNA-499) is a cardiac-specific 
miRNA that when elevated causes cardiomyocyte hypertrophy, in turn preventing 
cardiac dysfunction during MI. Previous studies revealed that the combination 
treatment of conjugated linoleic acid (cLA) and nitrite preserved cardiovascular 
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function in mice. Therefore, we hypothesized that cLA and nitrite may regulate 
miRNA-499, thus providing cardiac protection during MI. To test this hypothesis, 
12-week old mice were treated with cLA (10 mg/kg/d-via osmotic mini-pump) or 
cLA and nitrite (50 ppm-drinking water) 3 days prior to MI (ligation of the left 
anterior descending artery). Echocardiography and pressure-volume (PV)-loop 
analysis revealed that cLA and nitrite-treated MI mice had improved heart 
function (10 days following MI) compared to untreated MI mice. Treatment with 
cLA and nitrite significantly induced levels of miRNA-499 compared to untreated 
MI mice. In addition, treatment with cLA and nitrite abolished MI-induced protein 
expression of p53 and dynamin-related protein-1 (DRP-1). Moreover, the 
antioxidant enzyme expression of heme oxygenase-1 (HO-1) was elevated in MI 
mice treated with cLA and nitrite compared to untreated MI mice. Confocal 
imaging on heart tissue confirmed expression the levels of HO-1 and p53. Taken 
together, these results suggest that therapeutic treatment with cLA and nitrite 
may provide significant protection during MI through regulation of both cardiac 
specific miRNA-499 and upregulation of phase 2 antioxidant enzyme expression. 
As we demonstrate in our study cLA and nitrite co administration 
decreased apoptosis though the HO-1 and/or miRNA-499 pathway. To 
investigate more deeply the role of HO-1 and/or miRNA-499 in apoptosis, we 
used HO-1 Tg and HO-1 KO mice. Our data supported the hypothesis that HO-1 
regulates miRNA-499 levels and thus decreases apoptosis after MI. As others 
and we have demonstrated before, MI is known to cause cardiomyocyte 
ischemia, in turn, leading to cardiomyocyte apoptosis [1, 2]. The current study 
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extends previous findings by demonstrating that ischemia causes an increased 
ratio of Bax/Bcl-2 following MI in non-treated C57 mice and in HO-1 KO mice. 
Our data demonstrate that in HO-1 KO mice the expression of miRNA-499 is not 
detectable.  
Overall, these data reveal links among p53, HO-1, miRNA-499, and Drp1 
with regard to regulation of the apoptotic programed cell death in the heart. 
Taken together, these results suggest that therapeutic treatment with cLA and 
nitrite may provide cardiac protection during MI through the regulation of 
induction of cardiac specific HO-1 expression, which further regulated cardiac  
specific miRNA-499.  
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CHAPTER I 
INTRODUCTION 
 
A. Myocardial infarction 
Myocardial infarction (MI) caused by coronary artery blockage is the major 
cause of death worldwide [3]. Over the last two decades, health care 
professionals, consumers, and payer organizations have sought to improve 
outcomes for patients hospitalized with acute MI [4]. In the United States (US) 
alone, nearly 8 million people have a history of MI [5]. Subsequently, in 1990 the 
American College of Cardiology and the American Heart Association jointly 
published the first in a series of clinical practice guidelines for MI that include a 
significant emphasis on evidence-based hospital care [6].  
In 1992 the Health Care Financing Administration, now the Centers for 
Medicare & Medicaid Services (CMS), initiated an ongoing national effort, aided 
by quality improvement organizations, to measure and improve hospital care for 
patients with acute MI [7]. According to the World Health Organization, ischemic 
heart disease is one of the leading causes of death worldwide, with about 3.8 
million men and 3.4 million women dying yearly from this disease. In the US 
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ischemic heart disease resulting from coronary artery disease is devastating, with 
1.5 million US citizens developing MI-s that account for nearly 200,000 deaths 
per year [8, 9]. The National Heart, Lung, and Blood Institute estimate that an 
average of 14.2 years of life may be lost due to heart attack [10]. 
Acute MI remains a leading cause of morbidity and mortality worldwide 
[11]. MI occurs when myocardial ischemia, a diminished blood supply to the 
heart, exceeds a critical threshold and overwhelms myocardial cellular repair 
mechanisms designed to maintain normal operating function and homeostasis 
[12]. Ischemia at this critical threshold level for an extended period results in 
irreversible myocardial cell damage or death [13]. Critical myocardial ischemia 
can occur as a result of increased myocardial metabolic demand, decreased 
delivery of oxygen and nutrients to the myocardium via the coronary circulation, 
or both [14]. Acute MI results from blockage of a coronary artery leading to 
insufficient blood supply to cardiac tissue, ultimately resulting in cardiomyocyte 
death [15] and cardiac dysfunction [13]. MI is characterized by significant 
changes in gene expression, many of which represent adaptive or maladaptive 
responses to stress [16-20]. The resulting cardiac stress induces rapid changes 
in gene expression immediately following MI [21]. Cardiomyocyte cell death is a 
consequence of myocardial injury, which occurs as early as the initiation of acute 
MI [22]. Cardiomyocyte death or apoptosis is a key factor in transition from 
cardiac hypertrophy to heart failure [23]. 
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B. Apoptosis and myocardial infarction 
Apoptosis or programmed cell death is a highly regulated and energy 
requiring process [24]. Apoptosis is characterized by shrinkage of the cell and the 
nucleus [24]. The nuclear chromatin is cut into sharply defined masses, and 
eventually breaks up into the small particles [25]. At this stage, extensions bud 
out from their membranes, which eventually seal off to form membrane enclosed 
vesicles, called apoptotic bodies, containing condensed cellular organelles and 
nuclear fragments [25, 26]. These apoptotic bodies are either rapidly 
phagocytosed by neighboring cells or undergo degradation, which resembles 
necrosis in a process called secondary necrosis [26]. However, apoptosis is 
generally considered not to trigger an inflammatory response [27].  
Apoptosis plays a role in the tissue damage after MI, it has pathological 
and therapeutic implications [28]. Apoptosis is highly regulated and the 
consequences of the cellular mechanisms that control apoptosis during and/or 
after MI are well understood [26, 29]. Thus, the apoptotic pathway becomes an 
important therapeutic target with regard to attenuation of tissue damage in 
patients with MI and consequent heart failure. 
During MI-induced heart damage, cardiomyocyte apoptosis contributes to 
dilatation of the infarcted chamber, and thus leads to cardiac dysfunction or 
eventual heart rupture following MI [30]. MI represents one of the major etiologies 
that emphasizes the expansion of congestive heart failure [31]. Damage of 
cardiomyocytes secondary to prolonged ischemia has been thought to be 
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resulted from the manifestation of necrosis [32]. Whereas this form of cell death 
remains a main cause of tissue injury, recent studies have suggested that 
damage of cardiomyocytes after MI can also be caused by apoptosis [33-37]. 
Overall, myocyte death in MI is attributed to necrosis, but recently myocardial 
apoptosis has been observed in humans during acute MI [36, 37]. Apoptosis is 
the early manifestation of cell death in infarcted myocardium [38], which is  
primarily seen in cardiomyocytes in hypoxic regions during MI [36]. p53 is a well-
known transcription factor which mediates apoptosis by initiating the expression 
of pro-apoptotic genes, including Bax, caspase, etc. [39]. Previous studies have 
demonstrated that p53 transcriptional activity is enhanced in MI [40] and that p53 
plays a critical role in the regulation of hypoxia-induced apoptosis of 
cardiomyocytes [1]. Importantly, p53 signaling is proposed to be part of the pro-
apoptotic pathways which eventually lead to cardiac apoptosis [39]. Enlargement 
of the LV chamber is a distinctive alteration of the failing heart regardless of 
cause [31]. For example, chronic ventricular dilatation and failure can be an 
outcome of long-standing volume overload. LV chamber dilation is associated 
with the loss of cardiac myocytes [41]. Previous studies have shown that 
myocardial stretch is associated with cardiomyocyte apoptosis [42, 43]. More 
recent studies have shown that myocardial stretch alone, under conditions of 
acute or chronic volume overload, may be associated with cardiomyocyte loss 
through apoptosis [31]. 
Bcl-2, Bax and p53 have been recognized to play a significant role in the 
management of cell death and apoptosis [44]. Apoptosis is a tightly regulated 
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process, as previously mentioned, and the imbalance between Bax and Bcl-2 
proteins decides the outcome of the cell [38]. The expression of these regulatory 
proteins, Bcl-2 and Bax, has been studied following MI in cardiac tissue [45]. Bax 
is a member of the Bcl-2 family and its overexpression accelerates apoptosis [15, 
46]. It also counters the death repressor activity of Bcl-2, the Bcl-2 family proteins 
are involved in the p53 apoptotic pathway and the balance between those 
positively and negatively regulatory proteins is essential for forming apoptosis 
[47]. Bcl-2 is known as anti-apoptotic protein, and Bax is widely described as a 
pro-apoptotic factor, thus the balance between Bax and Bcl-2 contributes to the 
signaling of programmed cell death through apoptosis [47, 48]. It has been 
shown that Bcl-2 expression can inhibit apoptosis in ischemic cardiomyocytes 
after MI [49, 50] and myocardial ischemia induces a reduction in the expression 
of Bcl-2 protein and increases in the expression of Bax and p53 proteins [51, 52]. 
Therefore an imbalance in anti- and pro-apoptotic proteins expressed during 
myocardial ischemia is involved in initiating myocyte cell death [53, 54]. Overall, if 
the Bax to Bcl-2 ratio is high, this may indicate apoptotic cell death infarcted 
myocardium [45].  
 
 
 
 
6 
 
C. miRNA-499 protects the heart from apoptosis 
MicroRNAs (miRNAs) quantitatively regulate mature-RNAs, which affect 
the cardiac transcriptional output and cardiac function [55]. miRNAs are 
endogenous, single-stranded non-coding RNAs ranging 18 to 24 nucleotides in 
length, that play an important role in gene regulation [55, 56]. In screening for 
miRNAs enriched in the heart, miRNA-499 is abundant and is known to be an 
evolutionarily conserved muscle-specific microRNA that is encoded within the 
intron of myosin heavy chain and is highly expressed in the cardiac ventricles 
[55-57]. Plasma miRNA-499 is a known biomarker of acute MI, as plasma 
miRNA-499 has been observed in individuals with MI [58-60].  
The balance between cell proliferation and apoptosis is required for living 
cells and miRNA-499 plays a big role in maintaining this balance [61]. Previous 
studies show that overexpression of miRNA-499 reversed enhanced proliferation 
and shows an anti-apoptotic effect in cardiomyocytes [61].  
Ultimately, heart function is highly dependent on ATP generation. The 
heart is enriched with mitochondria that provide the energy required for 
cardiomyocyte function [62]. Therefore, it is known that mitochondria play a 
critical role in development and progression of many cardiac diseases such as 
hypertrophy and MI. Previous studies suggest that mitochondria are highly 
dynamic and that changes in mitochondrial shape can affect a variety of 
biological processes such as apoptosis and fibrosis [63, 64]. Mitochondria are 
organelles which constantly undergo fission and fusion [63-65]. These two 
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opposing processes are regulated by the mitochondrial fusion proteins mitofusin 
and the mitochondrial fission protein Drp-1 [62]. During apoptosis, Drp-1 foci 
accumulates on mitochondria and can enhance mitochondrial fission [66, 67]. 
miRNA-499 has been shown to be involved in inhibiting apoptosis and MI 
induced by anoxia and ischemia through mechanisms involving p53 and Drp-1 in 
accomplishing apoptosis in the MI heart [57]. The modulation of miRNA-499 may 
be a novel therapeutic approach to treat apoptosis-related cardiac disease, 
including MI [68, 69]. 
 
 
 
D. Cardio-protective effects of fatty acids 
Conjugated linoleic acid (cLA) refers to a group of positional and 
geometrical isomers of octadecadienoic acid, with two alternating double bonds. 
Rumen bacteria has the unique ability to convert linoleic acid into cLA via an 
enzymatic isomerase reaction, and therefore at least 28 possible isomers of 
linoleic acid as a naturally occurring trans fat are possible, and it is commonly 
found in ruminant animal sources such as beef, lamb, and dairy products (e.g., 
milk and cheese) [70]. Incidentally this is also where the concentrations are 
highest -beef, lamb, and dairy products [71-73]. Seafood, pork, most poultry 
products and vegetable oils are not notable sources of cLA [72, 73]. cLA has also 
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been identified as occurring naturally in foods such as white button mushrooms 
[74] and pomegranate seed oil [73]. 
 In addition to ingestion through ruminant food products, cLA is 
commercially available as a dietary supplement, prominent isomers are cis-9, 
trans-11-cLA and trans-10, cis-12-cLA, but cis-9, trans-11 accounts for 72-94% 
of total cLA in foods [9, 72].  There is emerging evidence that individual cLA 
isomers may be responsible for specific biological or biochemical changes in the 
body [75].  
Numerous studies have reported positive effects of cLA consumption, 
including weight loss in obese individuals [76], modulation of immune function 
[77, 78], anti-carcinogenic activity [79], protection against atherogenesis [80, 81], 
reversal of atherosclerosis [82], and normalization of glucose and insulin 
homeostasis in pre-diabetic animal models [83, 84].  However, recent studies 
from our lab suggest that cLA lowers survival in a murine model of myocardial 
ischemia, causing life threatening spontaneous ventricular tachycardia (VT) and 
sudden cardiac death (SCD) (Fig. 1).  In addition, we have previously shown that 
cLA treatment lowers physiological nitric oxide (NO) levels and impairs heart 
function in aged mice [85].  
 
 
 
 
 
9 
 
E. Heme oxygenase-1 in cardiovascular disease 
Recent literature suggests that dietary cLA and nitrite supplementation in 
rodents elevates nitrated-cLA (NO2-cLA) levels in the plasma and tissues, 
inducing heme oxygenase-1 (HO-1) expression in the target tissue [86]. HO-1 
catalyzes the oxidation of heme, producing biliverdin, iron, and carbon monoxide 
(CO) [87, 88]. Importantly, biliveridin is converted to bilirubin, a known potent 
antioxidant.  Additionally, iron can be sequestered by ferritin, leading to off target 
anti-apoptotic effects and carbon monoxide has similar characteristics to nitric 
oxide, facilitating numerous biological functions including anti-inflammatory 
effects [88-90]. Induction of HO-1 is considered an important cardioprotective 
response in the failing heart that reverses pathological LV remodeling, and this 
effect is mediated through inhibition of apoptosis [90]. Increased expression and 
activity of HO-1 represents a therapeutic strategy for amelioration of LV failure 
[90]. It has been shown that induction of HO-1, eliminates inflammatory response 
and apoptotic events after MI [91]. HO-1 increases oxidative stress resistance 
and eliminates apoptosis [92]. Apoptosis consists of multiple mechanisms during 
heart failure that produces increased activity of extrinsic pathways of cell death 
[93]. HO-1 becomes a very important part of treatment to reduce apoptosis after 
MI. 
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CHAPTER II 
 
HYPOTHESIS AND SPECIFIC AIM 
 
Overall aim 
 
MI affects over five million individuals in the US and remains a significant 
and yet unsolved health problem. MI results in an insufficient blood supply to 
cardiac tissue resulting in myocardial cell death and fibrosis [12, 94, 95]. MI is 
characterized by significant changes in gene expression, many of which 
represent adaptive or maladaptive responses to stress [16-20]. p53 is a well-
known transcription factor which mediates apoptosis by activating the 
manifestation of pro-apoptotic genes [96]. Thus, p53 becomes an important 
therapeutic target, with regard to attenuation of cardiac apoptosis and 
consequent heart failure.  
Recent literature suggests that dietary conjugated linoleic acid (cLA) and 
nitrite supplementation in rodents elevates nitrated cLA (NO2-cLA) levels in the 
plasma and tissues, inducing heme-oxygenase-1 (HO-1) expression in the target 
tissue [86]. HO-1 has anti-apoptotic effects and facilitates numerous biological 
functions including anti-inflammatory effects [88-90]. In addition, miRNA-499, a 
11 
 
cardiac specific microRNA, can attenuate apoptosis via regulation of the p53 
pathway [57]. Present data indicates that co-treatment with cLA and nitrite is 
cardio-protective through increased expression of miRNA-499 and HO-1, 
although the mechanism is unclear [97].  
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HYPOTHESIS 
Co-treatment with cLA and nitrite is protective in heart failure 
through induction of HO-1 expression in cardiac tissue, leading to 
regulation of miRNA-499 expression and a reduction of myocyte apoptosis. 
To address this hypothesis, this work will examine two aspects of the 
mechanism(s) involving HO-1 mediated miRNA-499 upregulation and heart 
function improvement following MI. 
Two specific aims are proposed to test this hypothesis:  
Specific aim 1: To determine whether the co-treatment with cLA and nitrite 
protects heart function in mice following MI. 
Hypothesis:  Co-treatment with cLA and nitrite reduces LV volume and diameter 
in mice following MI. 
Specific aim 2:  To determine whether co-treatment with cLA and nitrite 
increases HO-1 level in cardiac tissue, thereby increasing miRNA-499 and 
inhibiting p53-induced apoptosis. 
Hypothesis: HO-1 expression increases miRNA-499 and provides a cardio-
protective effect.
13 
 
CHAPTER III 
 
MATERIALS AND METHODS 
 
A. Materials:   
cLA (cis-9, trans-11 was purchased from NU-CHEKPREP, INC (Elysian, 
MN). Antibody against 4 Hydroxynonenal was purchased from Abcam 
(Burlingame, CA). Antibody against GAPDH was purchased from Trevigen, 
(Gaithersburg, MD), antibody against p53 was purchased from Calbiochem, 
(Billerica, MA) and antibody against HO-1 was purchased from Stressgen 
Biotechnologies, (Farmingdale, NY). TUNEL assay kit was purchased from 
Promega (Fitchburg, WI). 
 
B. Animals:  
Mice were fed standard chow and water ad libitum. All animal procedures 
were reviewed and approved by an independent Institutional Animal Care and 
Use Committee of the University of Louisville, School of Medicine.  In addition, all 
studies were performed in accordance with animal care and use guidelines of the 
National Institutes of Health.  
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C. Mouse model of MI:  
Male C57BL/6 mice, 10- to 12-wks old, were anesthetized with isoflurane, 
intubated and ventilated with CWE advanced ventilator (Webster,TX). Body 
temperature was maintained with an Indus Temperature feedback/surgical table 
and ECG system. Aseptic procedure was used for preparation of the surgical site 
through scrubbing with a 0.8% chlorhexidine solution. A left thoracotomy was 
performed via the fourth intercostal space and the lungs retracted to expose the 
heart. After opening the pericardium, the left anterior descending (LAD) coronary 
artery was ligated with an 8–0 silk suture near its origin between the pulmonary 
outflow tract and the edge of the atrium. Ligation was deemed successful when 
the anterior wall of the left ventricle (LV) became pale in color. The lungs were 
inflated by increasing positive end-expiratory pressure, and the thoracotomy side 
was closed in layers. The lungs were re-expanded, and the chest was closed. 
The animals were removed from the ventilator and allowed to recover on a 
heating pad. Mice were checked daily for signs of pain or distress and 
buprenorphine at 0.05mg/kg SQ is given before and every 12h for 48 hours. Mice 
were treated with cLA (10mg/kg/d-via osmotic mini-pump) or cLA + nitrite 
(50ppm-drinking water) 3 days prior to ligation of the LAD artery and treatment 
continued 10 days after ligation (Fig.2). 
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D. Measurement of Cardiac function: 
 
1. Echocardiography: 
 Mice were anesthetized with inhaled isoflurane and chest hair removed 
for baseline pre-MI and 10 days post-MI. Ultrasounds were obtained using a 
VisualSonics Vevo 2100 and a 40 MHz linear probe. Wall thickness and left 
ventricular cavity size were measured in at least 3 beats from each projection 
and averaged. Interventricular septum and posterior wall thickness, as well as 
internal dimensions at diastole and systole were measured.  In addition, LV 
fractional shortening, relative wall thickness, and LV mass were calculated from 
the M-mode measurements [98]. 
 
2. In vivo hemodynamic measurements: 
 Isoflurane was used to anesthetize the mouse and conductance readings 
were made for ~15-20 min prior to harvesting heart tissue. Briefly, the mouse 
was placed in a supine position on a 37°C pad under the surgical microscope 
and the limbs were restrained with tape. A 0.5cm skin incision was performed in 
the right neck area and the carotid artery was isolated using silk sutures.  The 
cranial aspect of the carotid artery was ligated and a microsurgical clip was 
placed on the proximal carotid artery for hemostasis. An arteriotomy was 
performed with microsurgical scissors, and a 1.2 French conductance catheter 
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(Transonic, London, ON, Canada) was introduced into the carotid artery and 
advanced retrograde across the aortic valve into the LV. The catheter was 
advanced under continuous hemodynamic monitoring to issue proper placement 
in the LV. The catheter was secured within the carotid artery with the proximal 
suture. LV pressure-volume loops were recorded in the steady state. Loops were 
recorded using the iWorks data acquisition software package, and analyzed 
using the LabScribe2 pressure-volume data analysis software package (iWorks, 
St. Albans, Vermont).  
 
E. Histology and confocal microscopy: 
Hearts were collected from the mice and thoroughly washed in PBS. 
Using Peel-A-Way disposable plastic tissue embedding molds (Polysciense Inc, 
Washington, PA) filled with tissue freezing media (Triangle Biomedical Sciences, 
Durham, NC), hearts were preserved and stored at -80 C until analysis. Tissue 
sections (5 µm in thickness) were made using a Leica CM 1850 Cryocut 
microtome (Bannockburn, IL, USA). Sections were placed on super frost plus 
glass slides, air-dried, and processed for Immunohistochemistry (IHC) staining. 
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1. Immunohistochemistry:  
Immunohistochemistry and laser-scanning confocal microscopy were used 
to visualize MI-induced changes in p53 and HO-1 expression and localization. 
Immunohistochemistry was performed on frozen tissue sections using a standard 
IHC protocol. Primary antibodies were applied overnight (anti-p53, Calbiochem 
and anti HO-1, Stressgen). Secondary antibodies labeled with Alexa Fluor 488 
and Alexa Fluor 568 (Invitrogen, Carlsbad, CA) were applied for protein 
immunodetection. Stained slides were analyzed for fluorescence using a laser 
scanning confocal microscope (Olympus FluoView-1000, objective 40X) set at 
the appropriate filter settings. The total fluorescence (green or red) intensity in 5 
random fields (for each experimental sample) was measured with image analysis 
software (Image-Pro Plus, Media Cybernetics). Fluorescence intensity values for 
each experimental group were averaged and presented as fluorescent intensity 
units (FIU). 
 
2. TUNEL assay: 
LV frozen sections were defrosted, and rehydrated with xylene and graded 
alcohol series. The sections were stained using the Apoptosis Detection System 
(Promega, Madison, WI) per the manufacturer's instructions. Briefly, the sections 
were incubated with terminal deoxynucleotidyl transferase and fluorescein-
labeled dUTP. To identify cardiomyocytes, sections were incubated with mouse 
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anti-myosin heavy chain monoclonal antibody (Chemicon International, 
Temecula, CA). Finally, to identify all nuclei (non-apoptotic and apoptotic), 
sections were stained with propidium iodide (Sigma-Aldrich, St Louis, MO). The 
samples were analyzed under a fluorescence microscope. Four sections 
randomly picked from each of four pieces were analyzed per animal. 
Cardiomyocyte nuclei were determined by random counting of 10 fields per 
section. The number of apoptotic nuclei was calculated per 10,000 
cardiomyocytes. 
 
 
F. Real-Time Quantitative PCR: 
Total heart tissue was isolated with TRIzol and RNA was isolated. 
Complimentary DNA was isolated using oligo (dT) primers (Promega 
Corporation, Madison, WI) and stored at -80° C until experiments were 
performed.  
 Reactions were done using 2000ng/uL cDNA and SYBR Green Master 
Mix (BioRad Laboratories, Hercules, CA). BioRad CFX Manager (BioRad 
Laboraties, Hercules, CA) software was used to analyze results. Gene 
expression was normalized with mRNA expression of 18S. Samples were 
analyzed in triplicate using N=3 for each independent experiment.  
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Primers: 
Mouse ANP: 
                      Forward:   5′-TGACAGGATTGGAGCCCAGAG-3′ 
                      Reverse:   5′-AGCTGCGTGACACACCACAAG-3′ 
Mouse BNP:  
                      Forward:   5′-ATCGGATCCGTCAGTCGTTTG-3′ 
                      Reverse:   5′-CCAGGCAGAGTCAGAAACTGGAG-3′ 
Mouse miRNA-499 
Forward:  5′-GGG-TGG-GCA-GCT-GTT-AAG-AC-3′   
Reverse:   5′-AGG-CAG-CAG-CAC-AGA-CTT-G -3′ 
Mouse DRP-1 
Forward:  5′-AAA CTC CTA TCA CGC TCA TCA-3′  
Reverse:  5′-CTC ATC CTC CAC GCA TCC T-3′ 
Mouse Bax 
Forward: 5‟- ATC AGA ACC ATC ATG GGC TGG ACA -3‟ 
Reverse: 5‟-AGC CAA TCT TCT TCC AGA TGG TGA -3‟ 
 
Mouse Bcl-2 
Forward: 5‟- AAA GCC AGT GTT CCA TGC ACC AAG -3‟ 
Reverse: 5‟- CAC ATG GCC GGC ACA CTT AAC ATT -3‟  
 
Mouse HO-1 
Forward:  5‟-TCA GTC CCA AAC GTC GCG GT-3‟ 
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Reverse:  5‟-GTC GTG CAG GRG TTG AGC C-3‟ 
 
Mouse 18S 
Forward: 5‟- AGA AAC GGC TAC CAC ATC CAA-3‟ 
Reverse: 5‟- GGG TCG GGA GGT AAT TT -3‟ 
 
 
G. Western Blot analysis: 
Heart tissue homogenate (100 μg) was electrophoresed using SDS-PAGE 
method as previously described [99, 100]. An affinity purified rabbit anti-GAPDH 
antibody (1:3000) was purchased from Trevigen (Gaithersburg, MD) and p53 
(1:1000) (Calbiochem) and HO-1 (1:1000) (Stressgen Biotechnologies) were 
detected using secondary antibodies. 
   
 
H. Cardiomyocyte isolation: 
Mouse cardiomyocytes were isolated from the whole heart by Liberase 
digestion as described previously with some modifications [101].  Briefly, mice 
were injected intraperitoneally with heparin (300 units) 30 min prior to sodium 
pentobarbital anesthetization (5 mg).  The heart was rapidly excised, placed in 
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ice-cold PBS and the aorta was rapidly cannulated with a blunted, 22 gauge 
needle.  The heart was then perfused in retrograde fashion with oxygenated 
Tyrode‟s solution maintained at 37°C to flush all blood from the coronary 
vasculature.  After 5 minutes, the perfusion solution was exchanged with the 
Liberase digestion solution and the heart was digested for approximately 8 
minutes.   The ventricles were then cut off the cannula and placed in the mincing 
solution in which heart tissue was teased apart with forceps and triturated using a 
serological pipette until cardiomyocytes were fully dispersed.  Cardiomyocytes 
were passed through a 100 mesh filter to remove any undigested material, an 
allowed to settle to aspirate most of the mincing solution.  The cardiomyocytes 
were suspended in re-suspension solution 1 and transferred to a 15mL tube and 
allowed to settle for 10 minutes.  This solution was aspirated, along with any 
unsettled, hypercontracted cardiomyocytes and replaced with re-suspension 
solution 2.  This process was repeated 5 times with increasing [Ca++] until only 
rod-shaped cardiomyocytes remained.  The cell pellet was then resuspended in 
culture media and cells were plated on laminin-coated 37mm cell culture dishes 
and incubated at in a 5% CO2 incubator at 37°C [101].   
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I. Cardiomyocyte treatment: 
Once plated, and at the appropriate confluence, cells were incubated with 
Culture media (500 mL MEM (GIBCO), 5mL Insulin-transferrin, selenium 
(GIBCO), 1% pen-strep, glutamine 2mM, NaHCO3 4mM, HEPES 10mM, BSA 
0.2%, BDM 1mg/ml) for 24 h. The cells were then treated with MeOH or 2.5 and 
5 μM cLA and nitrite [85]. 
 
J. Statistics:   
Data are shown as mean ± SEM.  The n values represent the number of 
independent experiments.  Each experiment was performed in triplicate unless 
otherwise indicated.  P values were calculated by Student‟s t-test or by one-way 
or two-way ANOVA, followed by Bonferroni analysis using GraphPad Prism 
software.  A P value <0.05 was considered statistically significant. 
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CHAPTER IV 
 
SPECIFIC AIM 1 
 
Specific aim 1: To determine whether the co-treatment with cLA and nitrite 
protects heart function in mice following MI. 
Hypothesis:  Co-treatment with cLA and nitrite reduces LV volume and diameter 
in mice following MI. 
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FIGURE 1 
 
Figure 1: Schematic diagram of overall hypothesis. Co-treatment with cLA 
and nitrite may enhance levels of HO-1 in heart tissue, leading to regulation of 
miRNA-499 and thus protecting heart from failure through induction of myocyte 
apoptosis. 
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Introduction 
MI, a result of coronary artery occlusion, is a major healthcare problem 
within the United States [4]. According to the CDC, the most common type of 
heart disease is coronary artery disease, which commonly leads to MI, 
approximately 720,000 people annually within the United States present clinically 
with MI, and the subsequent costs exceed $108.9 billion. Current therapies for 
coronary artery disease are mostly preventative measures, such as healthy diet, 
exercise, and weight loss, highlighting the need for further research into effective 
therapies for MI. MI results from blockage of a coronary artery leading to 
insufficient blood supply to cardiac tissue, ultimately resulting in cardiomyocyte 
death [15] and cardiac dysfunction [13]. 
cLA is an 18:2 fatty acid isomer of linoleic acid and the cis-9 trans-11 
isomer of cLA is the preferential fatty acid substrate for nitration, where nitration 
occurs only at positions 9 and 12 in vivo [86]. Co-treatment of cLA and nitrite in 
mice leads to an increase in nitrated-cLA within plasma and urine. 
This specific aim examines the effects of cLA with and without nitrite 
supplementation on cardiovascular injury following MI. Considering the initiative 
to replace saturated fats with so-called „healthy fats', to promote overall weight
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 loss and maintenance, the health effects of fats such as cLA require 
investigation. The principal findings demonstrated here, are that cLA is not 
protective in MI, but instead worsens survival after MI (Fig. 4). However, 
supplementation with nitrite in cLA-(10 mg/kg/d-via osmotic mini-pump) treated 
mice, leads to cardioprotection in MI injury. Specifically, cLA and nitrite co-
treatment significantly reduces LV dilatation (Fig. 6-8) after MI and improves 
heart function (Fig. 6-7).  
Atrial natriuretic peptide (ANP) is released from myocardial cells in the 
atria and in some cases the ventricles in response to volume overload and 
conceivably increased wall stress [102]. Brain natriuretic peptide (BNP) is initially 
identified in the brain but released primarily from the heart, particularly the 
ventricles [103]. The release of both ANP and BNP is increased in heart failure 
(HF), as ventricular cells are recruited to secrete both ANP and BNP in response 
to the high ventricular filling pressures [103]. 
4-HNE is a major and toxic aldehyde generated by free radical attack on 
ω-6 polyunsaturated fatty acids (arachidonic, linoleic, and linolenic acids) [104] 
and is considered a toxic messenger of oxygen free radicals [102, 103]. 4-HNE 
undergoes many reactions with various proteins, peptides, phospholipids, and 
nucleic acids; 4-HNE has a high biological activity and displays numerous 
cytotoxic, mutagenic, genotoxic, and signal effects [102, 103, 105], including 
inhibition of protein and DNA synthesis, inactivation of enzymes, modulation of 
platelet aggregation, and variety of the expression of numerous genes [104, 105]. 
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In addition, 4-HNE may be an important mediator of oxidative stress–induced 
apoptosis [104], cellular proliferation, and signaling pathways. cLA and nitrite 
supplementation ameliorates MI induced oxidative stress and supports 
cardioprotection in this MI model (Fig. 9).  Overall, cLA and nitrite mediate 
protection and result in improved heart function following MI. 
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Results: 
1.1 ST-segment elevation is an early marker of MI 
ECG was recorded during surgery, Fig. 3 A was recorded before surgery; 
Fig. 3 B was recorded after MI surgery. ST-segment elevation was recorded as 
an early sign of MI. After persistent ST-segment elevation on ECG, mouse chest 
was closed and moved to cage for recovery.  
 
1.2 Combination treatment with cLA and nitrite improves survival in MI 
mice  
Co-treatment of cLA and nitrite increased survival following MI. Survival in 
MI mice without treatment was between 70-80% and decreased to 35-40 % with 
cLA treatment. Survival following MI was improved with co-administration of cLA 
and nitrite (Fig. 4). 
 
1.3 Co-administration of cLA and nitrite increases heart weight and reduces 
LV volume   
Co-treatment of cLA and nitrite increased heart weight following MI. 
Hearts isolated from MI (10 days) and treated mice were found to be enlarged, 
with ventricular dilatation caused to increase EDV (Table 1). The heart weight / 
tibia length ratio was significantly increased in MI and single treated mice 
compared to control hearts, where co-administration cLA and nitrite was 
significantly higher than MI hearts with or without single treatment (Fig. 5).  
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1.4 Co-treatment with cLA and nitrite improve LV function following MI 
MI is characterized by ventricular chamber dilation and dysfunction (Table 
1). We observed a significant rightward shift of the PV loop in MI and single 
treated mice (Fig. 7). Chamber dilation also resulted in significant increase in 
both end-systolic and end-diastolic volume (Fig. 7, Table 1). As shown in Fig. 7, 
invasive hemodynamic measurements showed a reduction in EF in MI vs. the 
control groups (Fig. 7, Table 1). Treatment did not change EF in control animals 
(Fig. 7, Table 1). However, co-administration with cLA and nitrite shifted PV-loop 
to the left compared to MI PV-loop, indicating that the overall heart function is 
improved in cLA and nitrite-treated mice following MI. 
Ultrasound showed similar changes in MI mice. LV end diastolic and end-
systolic diameters were increased in mice, which caused LV Fraction Shortening 
(FS) reduction (Fig. 6). Treatment with cLA and nitrite improved LV function. FS 
was improved from 23% to 42% (Fig. 6).  
 
1.5 Co-administration of cLA and nitrite eliminates MI induces oxidative 
stress in LV ventricle after MI 
4-HNE is an indicator of lipid peroxidation and protein damage, and is 
considered to be a second toxic messenger of ROS [106]. There was brown 
pigmentation in tissue section from MI mice, which was a stain marker of 4-HNE-
positive cells (Fig. 8). Brown spots were ameliorated in mice treated with cLA and 
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nitrite, meaning oxidative stress was reduced in mice treated with cLA and nitrite 
following MI (Fig. 8).  
 
1.6 Co-treatment with cLA and nitrite eliminates apoptosis in ischemic zone 
of MI 
 TUNEL staining was used to detect apoptosis in LV of control, MI mice 
treated with or without cLA and nitrite. Apoptosis was detected in MI and single 
treated MI mice on ischemic part of LV (Fig. 9). Apoptosis was not visible in MI 
and single treated MI mice on non-ischemic part of LV (Fig. 9). Apoptosis was 
eliminated in MI mice treated with cLA and nitrite on ischemic zone of LV (Fig. 9). 
TUNEL staining did not stain the tissue from control mice (Fig. 9).  
 
 
1.7 Co-administration of cLA and nitrite decreases ANP and BNP- markers 
for heart failure after MI 
MI drastically increased ANP and BNP expression in heart, molecular 
markers of heart failure, by 4.2 and 3.4 fold, respectively (Fig. 10). However co-
administration of cLA and nitrite eliminated ANP and BNP expression following 
MI (Fig.10). Single treatment did protect heart from failure, as well as heart failure 
markers, ANP and BNP were increased by 4.2 and 2.9 fold respectively (Fig. 10).    
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FIGURE 2 
 
Figure 2: Experimental study design. Mice were treated with cLA, nitrite, and 
cLA and nitrite 3 days prior to MI surgery. On day 3, MI surgery was induced and 
after 10 days PV-loop analysis was performed. Mice were killed and tissue was 
collected for additional analysis.  
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                                                FIGURE 3 
 
 
 
 
 
 
Figure 3: ST segment elevation is an early marker of MI. ECG was recorded 
during MI surgery. A. ECG recorded before the MI surgery, B. ECG recorded 
during the MI surgery. C. Example of ST segment elevation. ST-segment 
elevation was the marker of successful coronary artery ligation. After ST-
segment elevation on ECG, the chest was closed and mouse was placed on a 
warming pad in the home cage for recovery.  
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FIGURE 4 
 
Figure 4: Co-treatment with cLA and nitrite increases survival in mice 
following MI. Survival was increased in cLA and nitrite treated mice following MI 
compare to single treated MI mice (*p<0.05 to MI cLA N, n=24 per group). 
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FIGURE 5 
 
 
 
 
 
 
 
 
 
Figure 5: Co-treatment with cLA and nitrite increases heart weight 
following MI. Heart weight was significantly increased following cLA or nitrite 
following MI, or in MI alone. cLA and nitrite co-treatment resulted in a further 
increase in heart weight, which was significant compared to MI alone. (*p<0.05 to 
control, #p<0.05 to MI, n=24 per group) 
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FIGURE 6 
 
Figure 6: Co-treatment with cLA and nitrite improves LV fraction shortening 
in mice following MI. A and D illustrate control mouse heart in B-mode and M-
mode respectively. B and E illustrate MI mouse heart in B-mode and M-mode-
respectively. C and F illustrate MI mouse heart treated with cLA and nitrite in B-
mode and M-mode respectively. G illustrates formula - how to calculate FS. 
(*p<0.05 to control, #p<0.05 to MI, n=24 per group)    
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FIGURE 7 
 
Figure 7: Co-treatment with cLA and nitrite significantly improves cardiac 
function after MI. Treatment with cLA exacerbated cardiac injury after MI, where 
combination treatment (supplementation with nitrite) rescued heart function 
following MI. (*p<0.05 to control, #p<0.05 to MI, n=10 per group). 
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FIGURE 8 
 
Figure 8: Co-treatment with cLA and nitrite reduces oxidative stress 
following MI. A. represents control heart tissue, where 4-HNE-brown pigment 
was not expressed. B, C, and D represent tissue from MI and single treated mice 
with cLA or nitrite, brown pigment stain-4-HNE was highly expressed in those 
samples. E represents tissue from the MI mouse heart, which was treated with 
cLA and nitrite, brown pigmentation-4-HNE was eliminated in this sample. F 
represents quantification using Adobe Photoshop.  (*p<0.05 to control, #p<0.05 to 
MI, n=10 per group). 
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FIGURE 9 
 
 
Figure 9: Co treatment with cLA and nitrite attenuates myocyte apoptosis 
following MI. Apoptosis was detected on tissue using TUNEL staining. Pictures 
were collected from ischemic zone (IZ) and from non-ischemic zone (NIZ) in MI 
mice. A represents confocal images from experimental groups, and B represents 
quantification using Adobe Photoshop.  (*p<0.05 to control, n=6 per group). 
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FIGURE 10 
 
Figure 10: Co-treatment with cLA and nitrite ameliorates heart failure 
markers following MI. relative fold changes of (A) ANP and (B) BNP expression 
in mouse hearts. ANP-atrial natriuretic peptide; BNP- B-type natriuretic peptide. 
(*p<0.05 to control, #p<0.05 to MI; n=6 per group).  
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TABLE 1 
 
 
 
Table 1: Hemodynamics of MI and control mice based on pressure-volume. All 
values are expressed as mean ± SD. BPM – beats per minute; ESP – end-
systolic pressure; EDP – end-diastolic pressure; ESV – end-systolic volume; 
EDV- end-diastolic volume, SV – stroke volume; CO – cardiac output; EF –
ejection fraction; (*p<0.05 to control, #p<0.05 to MI, n=10 per group). 
 
 
 
 
 
 HR   ESP  EDP  ESV  EDV  SV   CO   EF  
BPM  mmHg  mmHg  uL  uL  uL  ul/min  %
Control 552±1.79 80.88±0.49 6.95±0.67 15.43±0.37 40.66±1.72 25.23±1.53 13926.93±449.70 62.05±2.13
MI 555.78±8.67 78.36±3.72 2.73±1.25^ 55.43±3.72 * 72.77±2.40 * 17.66±3.72 * 9800.19±1218.05 * 23.00±4.17 *
MI+cLA 546.82±4.30 79.80±9.78 2.83±2.55^ 60.90±2.34 * 75.40±0.47 * 14.51±2.19 * 7644.82±1008.05 * 19.66±1.88 *
MI+N 538.98±12.14 75.75±0.85 3.77±0.10 59.21±4.57 * 75.46±3.89 * 16.23±1.93 * 8608.74±1898.04* 21.35±2.46 *
MI+cLA+N 556.82±4.30 85.79±0.75 10.26±3.26 30.90±2.34 *# 56.90±2.34 *# 26.56±2.36 # 14767.36±11213.05 # 45.42±2.13 *#
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Discussion 
Here we examine the effects of cLA with and without nitrite 
supplementation on cardiovascular injury following MI. Considering the initiative 
to replace saturated fats with so-called „healthy fats‟, to promote overall weight 
loss and maintenance, the health effects of fats such as cLA require further 
investigation. The principal findings demonstrated here, are that cLA is not 
protective in MI, but instead worsens survival following MI (Fig. 4).  However, 
supplementation with nitrite in cLA (10mg/kg/d-via osmotic mini-pump)-treated 
mice, leads to improved survival in mice following MI (Fig. 4). Specifically, cLA 
and nitrite co-treatment significantly decreases MI induced ANP and BNP mRNA 
levels following MI (fig. 10). Co-treatment with cLA and nitrite also decreases 
oxidative stress - 4-HNE expression following MI (Fig. 8). Overall, cLA and nitrite 
mediate protection and result in improved heart function and reduced LV volume 
in this murine model of MI (F. 6,7 and Table 1).  
Previous studies reported the correlation between hemodynamics and 
neurohumoral factors such as plasma cardiac natriuretic peptides, and plasma 
levels of ANP and BNP were thought to be a hemodynamic predictor in patients 
with CHF [105]. It is well known that plasma levels of ANP and BNP are markedly 
increased in patients with acute MI as well as in those with congestive heart 
failure [107, 108]. Our study shows increased ANP following MI and in single 
treated mice, which was lowered in cLA and nitrite treated mice (Fig. 10). Our 
physiological data demonstrates similar correlation with ANP and BNP, it shows 
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LV dilatation in MI and single treated mice, LV volume and diameter is decreased 
in cLA and nitrite treated MI mice (Fig 7, Table 1).  
A prominent lipid peroxidation product, 4-HNE, can be cytotoxic and is 
generated during various physiological and pathophysiological conditions based 
on the generation and cellular location of ROS [109, 110]. 4-HNE is also known 
as a measure of oxidative injury [111, 112]. Consequently, 4-HNE has biological 
relevance and displays a number of cytotoxic, mutagenic, genotoxic and further 
signal effects [113, 114]. Our data shows that 4-HNE was increased in MI and MI 
treated with cLA or nitrite mice, however oxidative stress was reduced after 
combination treatment with cLA and nitrite. cLA and nitrite supplementation 
ameliorates MI induced oxidative stress and supports cardioprotection in this MI 
model (Fig. 8). Overall, cLA and nitrite mediate protection and result in improved 
heart function following MI. 
Many studies have shown that TUNEL staining of nuclei to conclude that 
apoptosis occurs following MI [115]. The presence of apoptotic nuclei suggested 
that apoptosis was present in all cells in acute MI as a primary form of cell death 
[42]. LV remodeling during MI is characterized by progressive LV chamber 
dilation and systolic and diastolic dysfunction [116-118]. The LV remodeling 
involves cellular and molecular mechanisms at the site of infarction and the 
surviving unaffected area [119]. Myocyte apoptosis occurs in the ischemic zone 
of myocardium post MI [15, 34]. The amount of apoptotic myocytes correlates 
with an increase in the ventricular diameter after MI [119]. Apoptosis in the 
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infarcted area of myocardium plays a big role in LV remodeling after MI in mice 
[99]. Overall our study demonstrates that apoptosis was increased in MI and 
single treated MI mice, based on TUNEL staining of nuclei, which was reduced 
after combination treatment with cLA and nitrite (Fig. 9). As observed in our 
studies where we measured LV volume, TUNEL staining was reduced along with 
reduction of LV size and volume (Fig. 9, Table 1).  
Based on our data we conclude that treatment with cLA and nitrite 
reduces LV volume and LV size after MI, as well as reduces oxidative stress 
and attenuates apoptosis in ischemic area of myocardium after MI.  
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CHAPTER V 
 
SPECIFIC AIM 2 
 
Specific aim 2:  To determine whether co-treatment with cLA and nitrite 
increases HO-1 level in cardiac tissue, thereby increasing miRNA-499 and 
inhibiting p53-induced apoptosis. 
Hypothesis: HO-1 expression increases miRNA-499 and provides a 
cardioprotective effect.  
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FIGURE 11 
 
Figure 11: Schematic diagram of specific aim 2 hypothesis. Co-treatment 
with cLA and nitrite may enhance levels of HO-1 and/or miRNA-499 in heart 
tissue, leading to regulating oxidative stress and thus protecting heart from failure 
through induction of myocyte apoptosis 
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Introduction 
MI is characterized by significant changes in gene expression, many of 
which represent adaptive or maladaptive responses to stress [16-20]. The 
resulting cardiac stress induces rapid changes in gene expression immediately 
following MI [21]. Cardiomyocyte cell death is a consequence of myocardial 
injury, which occurs as early as the initiation of acute MI [22] . Cardiomyocyte 
death or apoptosis is a key factor in transition from cardiac hypertrophy to heart 
failure [23]. p53 is a well-known transcription factor which mediates apoptosis by 
activating the manifestation of pro-apoptotic genes [96]. Previous studies have 
demonstrated that p53 activity is enhanced during MI and that p53 plays a critical 
role in the regulation of hypoxia-induced apoptosis of cardiomyocytes [1, 40] . 
Thus, p53 becomes an important therapeutic target, with regard to attenuation of 
cardiac apoptosis and consequent heart failure. 
Apoptosis is controlled by several genes and the most crucial regulators 
are members of the Bcl-2 gene family. Bcl-2 is an anti-apoptotic gene that was 
first identified in follicular non-Hodgkin lymphoma [102, 104]. It has the capability 
to block an inclusive selection of apoptotic signals [103]. Bax is another member 
of the Bcl-2 family, but compared to Bcl-2 it has an apoptosis-stimulating function 
[105]. Gene products of the Bcl-2 family can form homo- and heterodimers with
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each other [107]. Therefore, it has been proposed that the cellular Bcl-2/Bax ratio 
is a key factor in the regulation of apoptosis; a high Bcl-2/Bax ratio makes cells 
resistant to apoptotic stimuli, while a low ratio induces cell death [108]. The Bax 
to Bcl-2 ratio is increased in cells induced to die by an apoptotic stimulus [107, 
108]. Therefore, the overexpression of Bax after MI may be related to the 
pathogenesis of apoptosis and congestive heart failure following MI. 
MicroRNAs quantitatively regulate mature-RNAs, which affect the cardiac 
transcriptional output and cardiac function [55]. miRNAs are endogenous, single-
stranded non-coding RNAs ranging from 18 to 24 nucleotides in length, that play 
an important role in gene regulation [55, 56]. In screening for miRNAs enriched in 
the heart, we found an abundant miRNA, miRNA-499, which is an evolutionarily 
conserved muscle-specific microRNA that is encoded within the intron of myosin 
heavy chain and is highly expressed in the cardiac ventricles [55-57]. Plasma 
miRNA-499 is known as a biomarker of acute MI, as plasma miRNA-499 has 
been observed in individuals with MI [58].  
Studies have shown that diets with diversified fats may be an effective 
strategy in decreasing risk of cardiovascular disease (CVD) [120, 121]. 
Conjugated linoleic acid (cLA) is a fatty acid that occurs as a mixture of positional 
and geometric isomers of linoleic acid (LA), which is produced in ruminant 
animals via an enzymatic isomerase reaction [122]. cLA contains 18 carbon 
atoms with two conjugated double bonds separated by a single bond [123]. cLA 
is found naturally in food products from these animals predominantly as the cis-
9,trans-11 form, whereas synthetic cLA preparations consist of a few different 
48 
 
isomers with an approximately equal amount of cis-9,trans- 11 and trans-10,cis-
12 cLA [121, 124]. Select modified fatty acids, such as nitrated fatty acids are 
known to induce pluripotent anti-inflammatory effects [125]. Recent literature 
suggests that dietary cLA and nitrite supplementation in rodents elevates NO2-
cLA levels in the plasma and tissues, inducing heme oxygenase-1 (HO-1) 
expression in the target tissue [86]. HO-1 catalyzes the oxidation of heme - 
producing biliverdin, iron, and carbon monoxide (CO) [87, 88]. Importantly, 
biliveridin is converted to bilirubin, a known potent antioxidant.  Additionally, iron 
can be sequestered by ferritin, leading to off target anti-apoptotic effects and 
carbon monoxide has similar characteristics to nitric oxide, facilitating numerous 
biological functions including anti-inflammatory effects [88-90]. 
Ultimately, heart function is highly dependent on ATP generation. The 
heart is enriched with mitochondria that provide the energy required for 
cardiomyocyte function [62]. Therefore, it is known that mitochondria play a 
critical role in the development and progression of many cardiac diseases such 
as hypertrophy and MI. Previous studies suggest that mitochondria are highly 
dynamic and that changes in mitochondrial shape can affect a variety of 
biological processes such as apoptosis and fibrosis [63, 64]. Mitochondria are 
dynamic organelles, which constantly undergo fission and fusion [63-65]. These 
two opposing processes are regulated by the mitochondrial fusion proteins 
mitofusin and the mitochondrial fission protein Drp-1 [62]. During apoptosis, Drp-
1 foci accumulates on mitochondria and can enhance mitochondrial fission [66, 
67]. 
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In the present study an in vivo model of MI is used to further elucidate the 
possible mechanism whereby combination treatment with cLA and nitrite is 
cardioprotective.  Herein we demonstrate that cLA and nitrite significantly 
induced levels of miRNA-499 in the heart compared to untreated MI mice.  
Additionally, co-treatment significantly reduced levels of p53 expression and 
induced expression of HO-1.  These results suggest that treatment with cLA and 
nitrite may provide significant protection during MI through regulation of cardiac 
specific miRNA and upregulation of phase 2 antioxidant enzyme expression.  
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Results: 
2.1 miRNA-499 biomarker of acute MI  
miRNA-499 was measured in isolated hearts from MI and control mice 
after 24h and 10 days after MI (Fig. 12). In the control, miRNA-499 almost had 
undetectable concentrations. Compared to the healthy control mice, miRNA-499 
levels were higher in MI mice after 24h (Fig. 12). Furthermore, the level of 
miRNA-499 was lowered in MI mice after 10 days compare to MI 24h mice (Fig. 
12). 
 
2.2 Co-treatment of cLA and nitrite regulates miRNA-499 during MI 
To investigate the specific role of miRNA-499 in regulation of improved 
heart function following MI, miRNA-499 levels were measured in the heart (Fig. 
13). miRNA-499 was increased following MI with combination treatment of cLA 
and nitrite (Fig. 13). There were no significant differences in single treated MI 
mice or with MI alone (Fig. 13). 
 
2.3 Mitochondrial fission factor DRP-1 is significantly increased in mice 
following MI 
MI caused a robust increase in Drp-1 expression in MI (Fig. 14). Individual 
treatments with cLA or nitrite increased expression of Drp-1 compared to control 
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mice, but the expression was overall lower than with MI-induction (Fig. 14). Co-
treatment with cLA and nitrite attenuated Drp-1 expression in MI mice (Fig. 14). 
 
2.4 cLA and nitrite treatment attenuates p53 expression following MI 
Expression of p53 was defined by immunohistochemical staining of cryo-
sectioned hearts (Fig. 15A). To support the immunohistochemical results that 
miRNA-499 blocks p53 after co-administration treatment with cLA and nitrite 
during MI, the level of p53 was assessed by Western blot analysis (Fig. 15B). 
The protein level of p53 was increased following MI and in single treated mice, 
but was abolished after co-treatment with cLA and nitrite (Fig. 15B). The p53 
staining support the data obtained via Western blot analysis (Fig. 15B). 
 
2.5 HO-1 expression increases in MI following cLA and nitrite treatment 
HO-1 expression was increased, as demonstrated using 
immunohistochemical staining of cryo-sectioned heart tissue (Fig. 15A). To 
support the hypothesis that co-treatment with cLA and nitrite during MI induces 
HO-1 level, the expression of HO-1 was assessed using Western blot analysis 
(Fig. 15B). Following treatment with cLA and nitrite, HO-1 protein expression is 
significantly increased (Fig. 15B). 
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2.6 Co-treatment with cLA and nitrite attenuates pro-apoptotic markers 
following MI 
The total Bax mRNA level was increased and the Bcl-2 mRNA level was 
decreased in the MI and single treated MI mice leading to an induction in the 
Bax/Bcl-2 ratio (Fig. 16). mRNA level of Bax was increased compared to control, 
levels were not as high as in MI and single treated MI mice (Fig. 16) and mRNA 
of Bcl-2 was not changed in cLA and nitrite treated MI mice.  Ratio of Bax/Bcl-2 
was induced in co-treated MI mice, but was lower than in MI and single treated 
mice (Fig. 16). 
 
2.7 Induction of HO-1 attenuates LV dysfunction in MI mice 
As we mentioned before, MI was characterized by ventricular chamber 
dilation and dysfunction (Table 2). We observed a significant rightward shift of 
the PV loop in MI mice (Fig. 18). Chamber dilation also resulted in significant 
increase in both end-systolic and end-diastolic volume (Fig. 18, Table 2). As 
shown in Fig. 8, invasive hemodynamic measurements showed a reduction in 
%EF in MI vs. the control groups (Fig. 18, Table 2). HO-1 Tg mice had 
decreased %EF compared to control mice (Fig. 18, Table 2). However, %EF in 
HO-1 Tg mice was higher than in WT MI mice (Fig. 8). 
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Ultrasound showed similar changes in MI mice. LV end diastolic and end-
systolic diameters were increased in mice, which caused LV Fractional 
Shortening (FS) reduction (Fig. 19). %FS in HO-1 Tg mice was improved 
following MI. FS was improved from 23% to 47% (Fig. 19).  
 
2.8 HO-1 attenuates p53 levels in HO-1 Tg mice following MI 
HO-1 protein level was greater in HO-1 Tg mice compared to C57 control 
mice (Fig. 20). As we demonstrated previously, HO-1 protein level was high in MI 
mice treated with cLA and nitrite. HO-1 protein level expression stayed high in 
HO-1 Tg mice compared to control HO-1 Tg control mice (Fig. 20). HO-1 protein 
level was not expressed in HO-1 KO mice regardless of treatment (Fig. 20). 
From the previously demonstrated blot we saw that p53 protein level was 
high in C57 mice compared to control. We demonstrated the same result in 
Figure 20. From the same blot we saw that p53 protein level was drastically 
increased in HO-1 KO control, HO-1 KO MI and HO-1 KO MI mice treated with 
cLA and nitrite (Fig. 20). The protein level was low in HO-1 Tg Control and MI 
mice (Fig. 20). 
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2.9 HO-1 induces miNRA-499 expression in mice following MI.  
To investigate the relationship between HO-1 and miRNA-499 we 
measured miRNA-499 level in HO-1 Tg and KO mice following treatment and MI 
surgery. miRNA-499 was high in HO-1 Tg control mice and was further increased 
after MI in HO-1 Tg mice (Fig. 21). miRNA-499 level was not expressed in HO-1 
KO mice regardless of treatment or surgery (Fig. 21).  
 
2.10 HO-1 attenuates ratio of Bax/Bcl-2 following MI 
The total Bax mRNA level was increased and the Bcl-2 mRNA level was 
decreased in the HO-1 KO mice regardless of the treatment (Fig. 22). mRNA 
level of Bax was increased in HO-1 KO mice compared to control, levels were 
higher compared to C57 MI mice (Fig. 22) and mRNA of Bcl-2 was low in HO-1 
KO mice (Fig. 22).  Ratio of Bax/Bcl-2 was induced in HO-1 Tg control and MI 
mice (Fig. 22).  
 
2.11 The heart failure markers (ANP and BNP) are lowered in HO-1 Tg 
mice after MI.   
To evaluate heart failure in HO-1 Tg and HO-1 KO mice after MI we 
measured expression of ANP and BNP (Fig. 23). Expression of ANP and BNP 
were markedly increased in C57 MI mice, those markers were farther increased 
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in HO-1 KO mice, which was 5 fold higher than in C57 MI mice (Fig. 23). ANP 
and BNP expression was not changed in HO-1 Tg mice after MI (Fig. 23).  
 
2.12 cLA and nitrite induces miRNA-499 and HO-1 expression in 
cardiomyocytes.  
For further investigation of the relationship between treatment miRNA-499 
and HO-1 level expression, we isolated myocytes from adult C57 mice and 
treated with two different doses of cLA and nitrite (Fig. 25). HO-1 and miRNA-499 
expression was increased in cardiomyocytes treated with 2.5uM cLA and nitrite 
(Fig. 25). The expression of both HO-1 and miRNA-499 was further increased in 
cardiomycytes treated with 5uM cLA and nitrite (Fig. 25).  
 
2.13 cLA and nitrite induces miRNA-499 through HO-1 induction in 
cardiomycytes 
 We investigated the direct relationship between HO-1 and miRNA-499 
using HO-1 Tg and HO-1 KO mice; we isolated myocytes and treated with cLA 
and nitrite. Expression of HO-1 was very high in HO-1 Tg control isolated 
cardiomyocyes compared to C57 control isolated cardiomyocytes (Fig. 27). 
Expression of HO-1 was increased in HO-1 Tg isolated cardiomyocytes treated 
with 5uM cLA and nitrite (Fig. 27). HO-1 was not expressed in HO-1 KO isolated 
cardiomyocytes regardless of treatment (Fig. 27).  Expression of miRNA-499 was 
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similar in HO-1 Tg mice. It was highly expressed in HO-1 Tg control isolated 
cardiomyocytes compared to C57 control isolated cardiomyocytes (Fig. 27). It 
was further increased in HO-1 Tg cardiomyocytes treated with 5uM cLA and 
nitrite mice (Fig. 27).  
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FIGURE 12 
 
Figure 12: miRNA-499 biomarker of acute MI. miRNA-499 was drastically 
increased after 24h of MI compared to control mice, which was lowered after 10 
days of MI compared to 24h MI mice. (*p<0.05 vs Control; # p<0.05 vs MI 24h 
n=6 per group) 
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FIGURE 13 
 
 
Figure13: Co-treatment with cLA and nitrite induces miRNA-499 following 
MI. miRNA-499 was significantly increased in MI mice after combination 
treatment with cLA and nitrite (*p<0.05 vs control, n=8 per group). 
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FIGURE 14 
 
Figure 14: Mitochondrial fission factor DRP-1 is attenuated in mice treated 
with cLA and nitrite following MI. Nitrite or cLA-treated MI mice had decreased 
levels of DRP-1 compared to MI alone. Combination treatment with cLA and 
nitrite significantly lowered the level of Drp-1 in MI mice, comparable to control 
values (*p<0.05 to control, 
#p<0.05 to MI, n=8 per group). 
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FIGURE 15 
 
Figure 15 A: Co-treatment with cLA and nitrite attenuates p53 and induces 
HO-1 expression following MI.  
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FIGURE 15 
 
Figure 15 B: Co-treatment with cLA and nitrite attenuates p53 and induces 
HO-1 expression following MI. Confocal microscopy (A): heart tissue was 
labeled with p53 (green), HO-1 (red), and cell nuclei were labeled with DAPI 
(blue). Western blot analysis reveals that p53 is significantly increased in cardiac 
tissue following MI (B). Quantitated protein expression reveals that co-
administration of cLA and nitrite lowers p53 levels, while increasing expression of 
HO-1 (*p<0.05; n=6 per group).  
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FIGURE 16 
 
 
Figure 16: Co-treatment with cLA and nitrite attenuates pre-apoptotic 
markers following MI. Expression of Bcl-2 and Bax in mice with/or without 
treatment following MI. (A-C) mRNA levels of Bcl-2 and Bax. (A) Higher Bax was 
observed in MI and single treated mice, which was lowered in cLA and nitrite 
treated mice (*p=0.05 vs control; #p=0.05 vs MI, N=6) and (B) lower Bcl-2 was 
observed in MI and single treated mice, which was restored in MI mice treated 
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with cLA and nitrite (*p=0.05 vs control; #p=0.05 vs MI, n=6 per group). (C) Ratio 
of Bax/Bcl-2 was high in MI and single treated mice which were lowered in MI 
mice treated with cLA and nitrite (*p=0.05 vs control; #p=0.05 vs MI, n=6 per 
group). (D) Schematic representation of relationship between Bax and Bcl-2. 
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FIGURE 17 
 
 
 
 
 
 
Figure 17: Schematic diagram of specific aim 2.2 hypothesis. 
Overexpression of HO-1 increased levels of miRNA-499 in heart after MI, 
resulting in inhibition of p53 and an overall improvement of heart function in MI 
mice.  
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FIGURE 18 
 
Figure 18: Induction of HO-1 attenuates LV dysfunction following MI. MI 
causes a drastic increase of End-diastolic volume in C57 mice (pink lines), which 
was protected in HO-1 Tg mice (red lines) compared to control (black lines). EF 
of C57 MI mice was decreased, 23%, HO-1 Tg mice EF-47% was decreased 
compared to control mice (EF-62%) but it was not as low as C57 MI mice. 
(*p<0.05 to control, #p<0.05 to MI, n=10 per group) 
 
66 
 
FIGURE 19 
 
Figure 19: Fraction shortening is protected in HO-1 Tg mice following MI. 
FS was decreased in C57 mice- 23% compared to control C57 mice-52%. FS of 
HO-1 Tg mice- 47% was lower compared to C57 control mice-52%, but was 
higher than in C57 MI mice-23%. (*p<0.05 to control, #p<0.05 to MI, n=24 per 
group) 
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FIGURE 20 
 
 
 
Figure 20: MI does not alter HO-1 levels in HO-1 Tg mice following MI. 
Examples of Western Blot images of the protein studied and contents of GAPDH 
in the respective samples (A). Relative protein expression is reported as fold 
change (B), alone (*p<0.05 to control, #p<0.05 to MI, n=24 per group) 
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FIGURE 21 
 
Figure 21: HO-1 induces miRNA-499 expression in mice following MI. The 
bar graph represents real-time PCR amplification of miRNA-499. miRNA-499 
was highly expressed in MI mice treated with cLA and nitrite and in HO-1 Tg 
mice with or without MI, miRNA-499 was not expressed in HO-1 KO mice 
regardless of treatment. (*p<0.05 to control, #p<0.05 to MI, n=6 per group) 
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FIGURE 22 
 
Figure 22: HO-1 attenuates apoptosis following MI. Expression of Bcl-2 and 
Bax in C57, HO-1KO and HO-1Tg mice with/or without treatment following MI. 
(A-C). Higher Bax was observed in C57 MI and HO-1 KO mice (A), which was 
lowered in cLA and nitrite treated mice and HO-1 Tg mice (*p=0.05 vs control; 
#p=0.05 vs MI, n=6 per group). Lower Bcl-2 was observed in C57 MI and HO-1 
KO mice, which was restored in MI mice treated with cLA and nitrite and HO-Tg 
mice (B) (*p=0.05 vs control; #p=0.05 vs MI, n=6 per group). (C) Ratio of 
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Bax/Bcl-2 was high in C57 MI and HO-1 KO mice which were lowered in MI mice 
treated with cLA and nitrite and HO-1 Tg mice (*p=0.05 vs control; #p=0.05 vs 
MI, n=6 per group). (D) Schematic representation of relationship between Bax 
and Bcl-2. 
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FIGURE 23 
 
Figure 23: HO-1 reduces heart failure markers after MI.  Relative fold change 
of (A) ANP and (B) BNP in C57, HO-1 KO, and HO-1 Tg mice before and after 
MI with/without treatment with cLA and nitrite. ANP-atrial natriuretic peptide; 
BNP- B-type natriuretic peptide. (*p=0.05 vs control; #p=0.05 vs MI, n=6 per 
group). 
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FIGURE 24 
 
Figure 24: Schematic diagram of specific aim 2 hypothesis.  
Co- treatment with cLA and nitrite induces level of HO-1 in myocytes.   
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FIGURE 25 
 
Figure 25: cLA and nitrite induces miRNA-499 and HO-1 expression in mice 
following MI. HO-1 expression was increased by 4 fold after 2.5uμM cLA and 
nitrite treatment. 5μM cLA and nitrite administration caused a 15 fold increase of 
HO-1 expression in C57 myocytes (A). miRNA-499 expression was increased for 
10 fold after 2.5μM  cLA and nitrite treatment. 5μM cLA and nitrite administration 
caused more than a 22 fold increase of miRNA-499 expression in C57 myocytes 
(B). (*p=0.05 vs control; #p=0.05 vs MI, n=6 per group). 
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FIGURE 26 
 
 
Figure 26:  Schematic diagram of specific aim 2 hypothesis. HO-1 is 
regulating the expression of miRNA-499 
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FIGURE 27 
 
Figure 27: cLA and nitrite induces miRNA-499 level through HO-1. HO-1 
expression was high before cLA and nitrite treatment in HO-1 Tg 
cardiomyocytes, HO-1 expression was increased further after 5μM cLA and nitrite 
administration (A). miRNA-499 expression was high in HO-1 Tg cardiomyocytes 
before treatment, which was increased further after 5μM cLA and nitrite 
administration (B). (*p=0.05 vs control; #p=0.05 vs MI, n=6 per group). 
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TABLE 2 
 
Table 2: Hemodynamics of C57 control, C57 MI and HO-1Tg MI mice based on 
pressure-volume. All values are expressed as mean ± SD. BPM – beats per 
minute; ESP – end-systolic pressure; EDP – end-diastolic pressure; ESV – end-
systolic volume; EDV- end-diastolic volume, SV – stroke volume; CO – cardiac 
output; EF –ejection fraction; (*p<0.05 to control, #p<0.05 to MI, n=10 per group). 
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Discussion 
This thesis examines the effects of cLA with and without nitrite 
supplementation on cardiovascular injury following MI. Considering the initiative 
to replace saturated fats with so-called „healthy fats‟, to promote overall weight 
loss and maintenance, the health effects of fats such as cLA require 
investigation. The principal findings demonstrated here is that cLA and nitrite co-
treatment significantly increases miRNA-499 and blocks mitochondrial fission 
through inhibition of p53 (Fig. 13, 14 and 15). Further, co-treatment with cLA and 
nitrite also induces HO-1 protein expression (Fig. 15), which supports cardio-
protection in this MI model. Overall, cLA and nitrite mediate protection and result 
in improved heart function in this murine model of MI.  
It is known that mitochondria undergo fission and fusion events 
continuously in non-disease states [126].  Mitochondrial morphological dynamics 
affect the outcome of ischemic heart damage and pathogenesis [126].  The Drp1 
protein plays an important role in fission, regulating mitochondrial membrane 
dynamics [65, 126, 127]. Drp1 exists as small oligomers, located primarily at the 
mitochondrial outer membrane.  These oligomers can connect to each other, 
forming larger multimeric structures, thus mediating mitochondrial division [16, 
65, 127, 128]. In previous studies Drp1 has been identified as a mediator of 
mitochondrial morphological changes and cell death during cardiac ischemic 
injury [128]. It has been reported that miRNA-499 affects DRP-1 mediated 
apoptosis and the severity of MI and cardiac dysfunction during heart disease 
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[57].  Our data suggest that MI significantly increases Drp1 expression in the 
heart of single treatment with cLA- and nitrite-treated, as well as in non-treated 
mice (Fig. 13).  Drp1 expression was abolished following co-treatment with cLA 
and nitrite in MI mice (Fig. 13).   
Bcl-2 gene families are identified as apoptosis regulating genes. Of these 
genes, Bax promotes cell death, whereas Bcl-2 inhibits apoptosis and promotes 
cell survival [108, 129]. The pro-apoptotic Bax gene shares structural similarities 
with Bcl-2 and is thought to inactivate Bcl-2 by binding to it [130]. The expression 
of Bax is dramatically increased in MI mice (Fig. 16), whereas a tendency toward 
a decrease in Bcl-2 expression is also revealed (Fig. 16). Although the threshold 
of Bax/Bcl-2 ratio at which apoptosis is triggered in the cardiac cell is not known, 
our data, together with others [131, 132], suggest that an increased Bax/Bcl-2 
ratio increases the probability for a myocardial cell to undergo apoptosis following 
MI (Fig. 16). The role of other pro-apoptotic and anti-apoptotic genes needs 
further investigation. 
There is evidence that miRNA-499 controls the apoptotic pathway 
thorough regulation of p53 [57]. Our data supports the hypothesis that miRNA-
499 decreases Drp1 levels after combination treatment with cLA and nitrite (Fig. 
11). MI is known to cause cardiomyocyte ischemia, in turn, leading to p53-
dependent cardiomyocyte apoptosis [1, 2]. The current study extends previous 
findings by demonstrating that ischemia causes increased expression of p53 
following MI in non-treated and cLA or nitrite-treated mice and provides 
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significant implications with regard to the molecular mechanism of cardiomyocyte 
apoptosis following MI (Fig. 15).     
  Previous studies have shown that pharmacological delivery of nitrated 
fatty acids leads to protection from cardiovascular injury [133, 134]. These 
studies have focused on protective signaling pathways including inhibition of p65 
subunit of NFκB and increased expression of HO-1. In a model of stenosis 
femoral artery injury, nitrated oleic acid induced vascular expression of HO-1, 
mediating protection against neointimal hyperplasia [134]. Nitrated oleic acid 
inhibited activation of NFκB in a murine model of ischemia reperfusion injury, 
resulting in reduction of infarct size [133]. More recent data suggests that dietary 
cLA is a privileged substrate for nitration reactions facilitated by mitochondria, 
digestion, and macrophage activation and following metabolic stress such as MI 
[86].  Co-administration of dietary cLA and nitrite supplementation raises NO2-
cLA levels in plasma and tissues, which in turn induces HO-1 expression in 
target organs [86].   
In the failing heart, HO-1 has anti-apoptotic effects by attenuating cell loss, 
p53 expression, and pathological heart remodeling [90].  Our data suggest that 
ratio of Bax/Bcl-2 was low in HO-1 Tg mice (Fig. 22), and it was drastically 
increased in HO-1KO mice after MI. Treatment with cLA and nitrite could not 
protect HO-1 KO hearts from apoptosis (Fig. 22). Heart failure marker expression 
supported apoptosis markers and physiological data (Fig. 18 and 22). ANP and 
BNP was low in HO-1 Tg mice following MI (Fig. 23), while those markers were 
80 
 
severely high in HO-1 KO mice regardless of treatment with cLA and nitrite (Fig. 
23).  
The important novelty of this thesis was to answer to the question: does 
HO-1 overexpression increase miRNA-499 levels, resulting in inhibition of p53 
level in heart tissue and an overall improvement of heart function in mice 
following MI (Fig. 17)?  
To answer this question we used HO-1 Tg and HO-1 KO mice. As we 
mentioned before, there are many studies showing that induction of HO-1 
resulted in cardiac protection during MI [90, 135-137]. Our data demonstrates 
similar results: MI in HO-1 Tg does not have drastic changes in LV function as in 
C57 mice (Fig. 18, 19 and Table 2). Western Blots supports the physiological 
data; HO-1 protein expression was markedly high in HO-1 Tg mice and was not 
expressed in HO-1 KO mice (Fig. 20), which explains the cardio-protective effect 
in HO-1 Tg mice, as their heart function was preserved compared to C57 MI mice 
(Fig. 18, 19 and Table 2).  
As we demonstrate in our study cLA and nitrite co-administration 
decreased apoptosis though the HO-1 and/or miRNA-499 pathway. To 
investigate more deeply the role of HO-1 and/or miRNA-499 in apoptosis, we 
used HO-1 Tg and HO-1 KO mice. Our data supported the hypothesis that HO-1 
regulates miRNA-499 levels and thus decreases apoptosis after MI. As others 
and we have demonstrated before, MI is known to cause cardiomyocyte 
ischemia, in turn, leading to cardiomyocyte apoptosis [1, 2]. The current study 
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extends previous findings by demonstrating that ischemia causes an increased 
ratio of Bax/Bcl-2 following MI in non-treated C57 mice and in HO-1 KO mice 
(Fig. 22). Our data demonstrate that in HO-1 KO mice the expression of miRNA-
499 is not detectable (Fig. 21).  
Treatment with cLA and nitrite increased expression of HO-1 in isolated 
cardiomyocytes from C57 and HO-1Tg mice (Fig. 25 and 26), as well as 
increased miRNA-499 level in isolated cardiomyocytes from C57 and HO-1 TG 
mice (Fig. 25 and 26). Data further suggests that co-administration of cLA and 
nitrite cannot increase the levels of HO-1 and meanwhile cannot change the 
levels of miRNA-499 in isolated cardiomyocytes from HO-1 KO mice (Fig. 25 and 
26). 
Overall, these data reveal mechanistic links between p53, HO-1, 
miRNA-499, and Drp1 with regard to regulation of the apoptotic programed 
cell death in the heart. Taken together, these results suggest that 
therapeutic treatment with cLA and nitrite may provide cardiac protection 
during MI through the regulation of induction of cardiac specific HO-1 
expression, which further regulated cardiac specific miRNA-499.  Further 
validation studies are required in small and large preclinical animal models 
with the goal of clinical translation. 
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CHAPTER VI 
 
IMPLICATION IN HEALTH AND DISEASE 
 
 
Multiple clinical trials support that the increased dietary intake of 
unsaturated fatty acids promotes a broad range of physiological benefits [86, 
138]. Results from Herbel reported a mean dietary cLA intake of 139 mg/d in 
young men and women [139], and Park‟s lab showed an estimated mean cLA 
intake in lactating women during periods of low and high dairy consumption of 20 
and 290 mg/d, respectively [140]. In summary, chronic as well as acute total cLA 
intake in men and women has not been reported to exceed 500 mg/d [141].  
Dairy products were the primary source of total cLA, followed by beef [70, 
73]. It has been identified that conjugated linoleic acid (cLA) is the preferential 
substrate for fatty acid nitration in humans [86]. Most importantly, it has been 
reported that cLA nitration occurs in healthy humans (as measured in plasma 
and urine) and may be increased in experimental models of inflammation upon 
oral delivery of cLA and inorganic nitrite (NO2) [86]. Because of the public 
concern with nitrite toxicity (the lethal dose in humans is about 22 milligrams per 
kilogram of body weight), the maximum allowed nitrite concentration in meat 
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products is 200 ppm [142]. Approximately 80 to 90% of the nitrite in the average 
U.S. diet is not from cured meat products, but from natural nitrite production from 
vegetable nitrate intake [142]. In our lab we have demonstrated that in mice, 
nitrite consumption together with cLA administration prevents heart failure, which 
may be one explanation for the apparent health effect of the Mediterranean diet 
[143]. 
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